Piper Jaffray (NYSE: PJC) will host its 23rd Annual Healthcare
Conference November 29–30 in New York. Industry participants and
investors will hear from more than 250 influential public and
private companies in the biotechnology, specialty pharmaceuticals,
drug discovery, medical technology, healthcare services, and
medical diagnostics and devices sectors.
“We have a longstanding commitment to the healthcare industry,”
said Jeff Klinefelter, head of equity research at Piper Jaffray.
“This is a time of dramatic change in healthcare driven by the pace
of numerous regulatory, managed care and commercial developments.
We expect investors to gain insights from leading biopharma,
medical technology and healthcare services companies.”
The 23rd Annual Piper Jaffray Healthcare Conference will feature
the industry’s leading senior management teams presenting to an
audience of nearly 1,500 attendees, including top institutional
investors, equity portfolio managers and research analysts from the
United States, the United Kingdom, Asia and Europe.
Featured companies include: Aastrom Biosciences, Inc.; Abaxis
Inc.; ABIOMED, Inc.; Acceleron Pharma, Inc.; Accuray Incorporated;
AcelRx Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc.;
Acorda Therapeutics, Inc.; Advisory Board Co.; Æterna Zentaris
Inc.; Affymetrix, Inc.; Akorn, Inc.; Alder Biopharmaceuticals,
Inc.; Alexion Pharmaceuticals, Inc.; Algeta ASA; Allergan Inc.;
Allon Therapeutics, Inc.; Allscripts Healthcare Solutions, Inc.;
Alnylam Pharmaceuticals, Inc.; Alphatec Holdings, Inc.; AMAG
Pharmaceuticals, Inc.; AmSurg Corp.; Amylin Pharmaceuticals, Inc.;
AngioChem Inc.; AngioDynamics Inc.; AngioScore, Inc.; Anthera
Pharmaceuticals, Inc.; Ardea Biosciences; Arena Pharmaceuticals,
Inc.; Array BioPharma Inc.; ArthroCare Corporation; Astex
Pharmaceuticals, Inc.; Athersys, Inc.; AtriCure, Inc.; Avanir
Pharmaceuticals; Avantis Medical Systems, Inc.; AVI Biopharma,
Inc.; Baxano, Inc.; Baxter International Inc.; Becton, Dickinson
and Company; Benefitfocus.com, Inc.; BG Medicine, Inc.; BioDelivery
Sciences International, Inc.; BioHorizons, Inc.; bioMerieux; Boston
Scientific Corporation; Cardica Inc.; Cardiocore Lab, Inc.;
CardioDx, Inc.; CardioFocus, Inc.; Celgene Corporation; Cellnovo
Limited; Celsion Corp.; Cepheid; Cerner Corporation; Chelsea
Therapeutics International Ltd; Chimerix, Inc.; China Kanghui
Holdings; Colibri Heart Valve; Complete Genomics, Inc.; Computer
Programs And Systems Inc.; Conceptus, Inc.; Concert
Pharmaceuticals, Inc.; CONMED Corporation; Covidien, Ltd.;
CryoLife, Inc.; Curaspan Health Group, Inc.; Curis Inc.; Cutera,
Inc.; CVRx, Inc.; Cyberonics, Inc.; Derma Sciences Inc.; DexCom,
Inc.; DFine, Inc.; DURECT Corporation; DynaVox Inc.; e+CancerCare;
EBR Systems, Inc.; Emergent BioSolutions, Inc.; Endo
Pharmaceuticals Holdings Inc.; Endologix Inc.; EnteroMedics, Inc.;
Exact Sciences Corporation; Exactech Inc.; Exelixis, Inc.; Flexion
Therapeutics, Inc.; Fluidigm Corporation; Fresenius Medical Care
AG; Genesis Biopharma, Inc.; GenMark Diagnostics, Inc.; Genomic
Health, Inc.; Gen-Probe Incorporated; GetWellNetwork, Inc.; Gilead
Sciences, Inc.; Greatbatch, Inc.; Hansen Medical, Inc.;
HEALTHCAREfirst Inc.; Healthland, Inc.; Healthpoint
Biotherapeutics; Healthways, Inc.; HeartWare International Inc.;
Heat Biologics, Inc.; Hill-Rom Holdings, Inc.; HMS Holdings Corp.;
Home Solutions, Inc.; Human Genome Sciences, Inc.; ICU Medical,
Inc.; IDEV Technologies, Inc.; Illumina, Inc.; Impax Laboratories,
Inc.; Imprivata, Inc.; Incyte Corporation; Infinity
Pharmaceuticals, Inc.; Inhibitex, Inc.; Inogen, Inc.; Insite Vision
Inc.; Insulet Corporation; Integra LifeSciences Holdings
Corporation; IntegraMed America Inc.; Integrated Diagnostics
Incorporated; IntelliPharmaCeutics International Inc.; InTouch
Technologies, Inc.; Intrexon Corporation; Intuity Medical, Inc.;
InVivo Therapeutics Holdings Corp.; IPC The Hospitalist Co.; IRIS
International Inc.; iScience Interventional, Inc.; ISIS
Pharmaceuticals Inc.; Jazz Pharmaceuticals, Inc.; Johnson &
Johnson; K2M Inc.; Kips Bay Medical, Inc.; KnowledgePoint360 Group,
L.L.C.; LipoScience, Inc.; Lutonix Inc.; MAKO Surgical Corp;
MannKind Corp.; Masimo Corporation; MedAssets, Inc.; Medgenics,
Inc.; Medicis Pharmaceutical Corp.; MEDISISS; Medivation, Inc.;
MEDNAX, Inc.; MedQuist Holdings, Inc.; Medtronic, Inc.; MELA
Sciences, Inc.; Merit Medical Systems, Inc.; Mesoblast Limited;
Metabolex, Inc.; Metabolon, Inc.; MethylGene Inc.; Micromet, Inc.;
Mindray Medical International; Morphosys AG; MWI Veterinary Supply,
Inc.; Myriad Genetics, Inc.; Nanosphere, Inc.; National Research
Corp.; Natus Medical Inc.; NDS Surgical Imaging, LLC; Nektar
Therapeutics; NeoMend, Inc.; Neurocrine Biosciences Inc.; New
American Therapeutics, Inc.; Novadaq Technologies Inc.; Novavax,
Inc.; Novo Nordisk A/S; NuPathe, Inc.; NuVasive, Inc.; Nuvo
Research Inc.; Nxstage Medical, Inc.; Obagi Medical Products, Inc.;
Omeros Corporation; Omnicell, Inc.; OMNIlife science, Inc.; Omthera
Pharmaceuticals, Inc.; Oncolytics Biotech Inc.; OncoMed
Pharmaceuticals, Inc.; OptiMedica; OraSure Technologies Inc.;
Orthofix International NV; Osiris Therapeutics, Inc.; Oxygen
Biotherapeutics, Inc.; Pacific Biosciences of California, Inc.;
Pacira Pharmaceuticals, Inc.; Pathwork Diagnostics, Inc.;
PatientKeeper, Inc.; Patterson Companies Inc.; PDI, Inc.; Pearl
Therapeutics, Inc.; Peregrine Pharmaceuticals Inc.; PerfectServe,
Inc.; Pernix Therapeutics Holdings, Inc.; Pharmasset, Inc.;
PharmAthene, Inc.; POZEN Inc.; Precision Dynamics Corporation;
Precision Therapeutics, Inc.; Pulmonx Corporation; QIAGEN N.V.;
Quality Systems, Inc.; Questcor Pharmaceuticals, Inc. ; Quidel
Corp.; RedBrick Health Corporation; Regeneron Pharmaceuticals Inc.;
Regulus Therapeutics, LLC; ResMed Inc.; REVA Medical, Inc.; Revance
Therapeutics, Inc.; Rigel Pharmaceuticals; Rochester Medical Corp.;
Salix Pharmaceuticals, Ltd.; Santarus Inc.; SANUWAVE Health, Inc.;
SciClone Pharmaceuticals, Inc.; Seattle Genetics Inc.; Sequenom
Inc.; Shanghai Kinetic Medical Co., Ltd.; Signature Diagnostics AG;
Sinovac Biotech Ltd.; Sonitus Medical Inc.; St. Jude Medical, Inc.;
STAAR Surgical Company; Steris Corp.; Sunshine Heart Inc.;
superDimension, Ltd.; SuperNova Diagnostics, Inc.; SurModics Inc.;
Suture Express, Inc.; Symmetry Medical Inc.; Team Health Holdings,
Inc.; TearLab Corporation; TEI Biosciences, Inc.; Tengion, Inc.;
Teva Pharmaceutical Industries Limited; The Spectranetics
Corporation; Theravance Inc.; Thoratec Corporation; Topera, Inc.;
Tornier N.V.; TranS1 Inc.; Tranzyme, Inc.; Trius Therapeutics,
Inc.; TyRx Pharma, Inc.; Ulthera Inc.; UnitedHealth Group, Inc.;
Vascular Solutions Inc.; VBI Vaccines; VCA Antech, Inc.; Vertex
Pharmaceuticals Inc.; VertiFlex, Inc.; Vertos Medical, Inc.;
ViroPharma Incorporated; Volcano Corporation; Watson
Pharmaceuticals, Inc.; Wright Medical Group, Inc.; XDx, Inc.;
XenoPort, Inc.; Zalicus Inc.; ZIOPHARM Oncology, Inc.; Zogenix,
Inc.; Zoll Medical Corp.
Company and investor participation in the Piper Jaffray
Healthcare Conference is by invitation only. Clients interested in
attending should contact their Piper Jaffray representative.
General and research-related media inquiries should be directed to
AnalystMediaRelations@pjc.com. Investment banking-related media
inquiries should be directed to Julie Lewis at
julie.a.lewis@pjc.com.
About Piper Jaffray
Piper Jaffray is a leading middle-market investment bank and
asset management firm serving clients in the U.S. and
internationally. Our proven advisory teams combine deep product and
sector expertise with ready access to global capital. Founded in
1895, the firm is headquartered in Minneapolis with offices across
the United States and in Hong Kong, London and Zurich.
www.piperjaffray.com
Since 1895. Member SIPC & NYSE.© 2011 Piper Jaffray &
Co.
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Oct 2023 to Oct 2024